AnaptysBio, Inc. short interest in 2026
In 2026, AnaptysBio, Inc.'s disclosed short interest ran from 20.11% of shares outstanding on 15 Jan 2026 to 18.68% on 15 Sep 2026, a change of -1.43 percentage points. The year's high was 20.46% on 30 Jan 2026 and its low 14.83% on 15 Apr 2026, averaging 17.83% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 17.99 days on 27 Feb 2026. Full history: AnaptysBio, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 20.11% (15 Jan 2026)
- End of year
- 18.68% (15 Sep 2026)
- Change
- -1.43 pp
- High
- 20.46% (30 Jan 2026)
- Low
- 14.83% (15 Apr 2026)
- Average
- 17.83%
- Highest days to cover
- 17.99 (27 Feb 2026)
- SEC filings marked
- 5
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 20.11% | 8.64 | results (8-K) |
| 30 Jan 2026 | 20.46% | 17.56 | |
| 13 Feb 2026 | 20.35% | 10.07 | |
| 27 Feb 2026 | 19.38% | 17.99 | |
| 13 Mar 2026 | 17.31% | 7.56 | 10-K filed, results (8-K) |
| 31 Mar 2026 | 17.38% | 6.93 | |
| 15 Apr 2026 | 14.83% | 7.97 | |
| 30 Apr 2026 | 15.33% | 5.47 | |
| 15 May 2026 | 16.48% | 7.26 | 10-Q filed, results (8-K) |
| 29 May 2026 | 16.57% | 9.85 | |
| 15 Jun 2026 | 15.92% | 8.17 | |
| 30 Jun 2026 | 17.69% | 8.27 | |
| 15 Jul 2026 | 17.18% | 5.86 | |
| 31 Jul 2026 | 18.56% | 7.21 | |
| 14 Aug 2026 | 18.27% | 14.29 | |
| 31 Aug 2026 | 18.60% | 15.59 | |
| 15 Sep 2026 | 18.68% | 10.25 |
See also: AnaptysBio, Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.